Table 1.
Baseline values and sources of data for selected variables used to estimate the cost-effectiveness of aspirin use among people with diabetes (costs in 2006 U.S. dollars)
| Parameter (reference number) | Base-case estimates |
|---|---|
| Relative risk of primary prevention | RR (95% CI) |
| Major coronary events (14) | 0.82 (0.75–0.90) |
| Overall stroke (14) | 0.95 (0.85–1.06) |
| Hemorrhagic (14) | 1.32 (1.00–1.75) |
| Ischemic (14) | 0.86 (0.74–1.00) |
| Relative risk of secondary prevention | |
| Major coronary events (14) | 0.80 (0.73–0.88) |
| Annual risk for side effects | % (95% CI) |
| Gastrointestinal bleeding (14) | 0.0003 (0.0002–0.0005) |
| Death resulting from gastrointestinal bleeding (18) | 0.00001 (0.000001–0.0001) |
| Annual cost* | 0.001 (0.001–0.01) |
| Aspirin† | 24 |
| MI (15) | |
| Year 1 | 7,765 |
| Ongoing annual cost after year 1 | 2,006 |
| Stroke (15) | |
| Year 1 | 67,347 |
| Ongoing annual cost after year 1 | 26,553 |
| Gastrointestinal bleeding (18) | |
| Nonfatal | 7,842 |
| Fatal | 7,842 |
| Utility score (17) | |
| Diabetes without complications | 0.689 |
| MI | 0.637 |
| Stroke | 0.617 |
| Gastrointestinal bleeding | 0.970 |
Data are point estimate (95% CI) unless otherwise indicated.
*Per person with newly diagnosed type 2 diabetes.
†Averaging the price of Bayer low-dose aspirin (i.e., baby aspirin) at several large chain pharmacies in the U.S.